New Zealand markets closed

Insulet Corporation (PODD)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
164.17-3.08 (-1.84%)
At close: 04:00PM EDT
163.80 -0.37 (-0.23%)
After hours: 07:04PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close167.25
Open166.64
Bid164.11 x 100
Ask164.26 x 100
Day's range160.38 - 166.64
52-week range125.82 - 335.91
Volume856,511
Avg. volume869,170
Market cap11.496B
Beta (5Y monthly)1.00
PE ratio (TTM)55.84
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Insulet to Announce First Quarter 2024 Financial Results on May 9, 2024

    ACTON, Mass., April 03, 2024--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the first quarter of 2024 on May 9, 2024 after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time).

  • Business Wire

    Insulet Appoints Ana Maria Chadwick as Chief Financial Officer

    ACTON, Mass., March 20, 2024--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that Ana Maria Chadwick has been appointed Executive Vice President, Chief Financial Officer and Treasurer, effective April 22, 2024. Today’s announcement concludes an extensive search process conducted by the Company.

  • Business Wire

    Insulet’s Randomized Controlled Trial (OP5-003) Demonstrates Omnipod® 5 Automated Insulin Delivery System is Superior to Pump Therapy

    ACTON, Mass., March 08, 2024--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today presented positive results from its first randomized controlled trial (RCT) showing improved glycemic and patient-reported outcomes in type 1 diabetes with the Omnipod 5 Automated Insulin Delivery System (Omnipod 5). The OP5-003 Trial results were presented at the 17th International Conference on Advanced Techn